BMRN - BioMarin Pharmaceutical Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
86.00
+2.29 (+2.74%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close83.71
Open83.58
Bid84.00 x 1100
Ask0.00 x 1800
Day's Range83.58 - 87.19
52 Week Range79.13 - 106.74
Volume1,210,232
Avg. Volume991,682
Market Cap15.34B
Beta (3Y Monthly)1.48
PE Ratio (TTM)N/A
EPS (TTM)-0.44
Earnings DateApr 25, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est119.46
Trade prices are not sourced from all markets
  • MoneyShow22 hours ago

    Long-Term "GameChangers" in Biotech

    When I'm hunting for unicorns, I start with biotech. They won't all be winners. But in a well-constructed portfolio, enough of them will hit their commercial targets with sufficient force to make their shareholders very happy, explains Hilary Kramer, editor of GameChangers.

  • Benzinga3 days ago

    The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

    Biotech stocks are on track to extend their losses, bucking the positive broader market sentiment. The week saw Achaogen Inc (NASDAQ: AKAO ) filing for Chapter 11 bankruptcy and negative clinical readouts ...

  • Earnings Preview: BioMarin Pharmaceutical (BMRN) Q1 Earnings Expected to Decline
    Zacks6 days ago

    Earnings Preview: BioMarin Pharmaceutical (BMRN) Q1 Earnings Expected to Decline

    BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Forbes Names BioMarin 4th Best Midsize Employer in America
    PR Newswire7 days ago

    Forbes Names BioMarin 4th Best Midsize Employer in America

    SAN RAFAEL, Calif., April 17, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) announced today that it has been ranked fourth on Forbes magazine's 2019 list of "America's Best Midsize Employers," increasing from 51st on last year's 2018 list. BioMarin was ranked first among its peers in the 'Drugs & Biotechnology' industry. "We are honored to again be named one of Forbes Best Employers.

  • CNBC7 days ago

    As Nasdaq 100 hits record, Apple and Intel could still be buys, says expert

    The Nasdaq 100 just hit a record, but that doesn't mean buying tech is off the table, one expert says. The tech-heavy index made an all-time high Wednesday morning, helped by a 4% surge in shares of Intel INTC . "I think Intel had the most constructive pullback to those December lows, which was a double bottom," Baruch said Tuesday on CNBC's "Trading Nation," pointing to the semiconductor company's three-year chart.

  • New Strong Sell Stocks for April 16th
    Zacks8 days ago

    New Strong Sell Stocks for April 16th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today

  • 8 Stocks May Jump on Takeovers as Market Nears Peak
    Investopedia12 days ago

    8 Stocks May Jump on Takeovers as Market Nears Peak

    Both JPMorgan and Deloitte expect strong merger and acquisition activity ahead, and analysts believe that these stocks are likely targets.

  • FireEye joins major Bay Area employers like Facebook, Netflix, Google, Microsoft and Salesforce in paying a typical worker more than $150,000 per year
    American City Business Journals14 days ago

    FireEye joins major Bay Area employers like Facebook, Netflix, Google, Microsoft and Salesforce in paying a typical worker more than $150,000 per year

    A small handful of the Bay Area's largest tech employers, including Facebook, Palo Alto Networks, Splunk and Broadcom, pay their median employee above $200,000 per year.

  • Markit15 days ago

    See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

    Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRNView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for BMRN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding BMRN is favorable, with net inflows of $114.25 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Does Sangamo Have the Best Gene Therapy Program Now?
    Motley Fool21 days ago

    Does Sangamo Have the Best Gene Therapy Program Now?

    The grandaddy of gene-editing stocks recently provided an encouraging update, but it isn't the only experimental hemophilia therapy out there.

  • Elon Musk’s CEO pay-to-worker ratio is the highest ever recorded — how it compares at other tech companies
    American City Business Journals22 days ago

    Elon Musk’s CEO pay-to-worker ratio is the highest ever recorded — how it compares at other tech companies

    Tesla last year awarded CEO Elon Musk a stock options package worth $2.28 billion — which works out to some 40,668 times more than what the company’s median worker earns in a year.

  • PR Newswire22 days ago

    BioMarin to Host First Quarter 2019 Financial Results Conference Call and Webcast on Thursday, April 25 at 4:30pm ET

    SAN RAFAEL, Calif. , April 2, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...

  • Were Hedge Funds Right About BioMarin Pharmaceutical Inc. (BMRN) ?
    Insider Monkey23 days ago

    Were Hedge Funds Right About BioMarin Pharmaceutical Inc. (BMRN) ?

    World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]

  • New Strong Sell Stocks for March 29th
    Zacks26 days ago

    New Strong Sell Stocks for March 29th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.

  • New Strong Sell Stocks for March 27th
    Zacks28 days ago

    New Strong Sell Stocks for March 27th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today:

  • Zacks28 days ago

    S&P Fights Past Growth Concerns to Reclaim 2800

    S&P; Fights Past Growth Concerns to Reclaim 2800

  • 3 Stocks to Buy Ahead of the Next Market Crash
    Motley Foollast month

    3 Stocks to Buy Ahead of the Next Market Crash

    BioMarin, Waste Management, and Walmart are three top defensive picks worth buying now.

  • Why Is BioMarin (BMRN) Down 0.9% Since Last Earnings Report?
    Zackslast month

    Why Is BioMarin (BMRN) Down 0.9% Since Last Earnings Report?

    BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Analysts Are Mostly Positive on BioMarin Pharmaceutical in March
    Market Realistlast month

    Analysts Are Mostly Positive on BioMarin Pharmaceutical in March

    How Major Rare Disease Pharma Stocks Are Positioned in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 32.04% for BioMarin Pharmaceutical (BMRN) based on the stock’s

  • American City Business Journalslast month

    S.F. hotel demand bubbles over, spilling out into the rest of the Bay Area

    Even in development-averse Marin, new hotel proposals are being stuffed into the Bay Area pipeline in an effort to meet accelerating demand.

  • New Strong Sell Stocks for March 18th
    Zackslast month

    New Strong Sell Stocks for March 18th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today

  • Zackslast month

    Boeing Keeps Dow from Joining Rally

    Boeing Keeps Dow from Joining Rally

  • Did BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Insiders Sell Shares?
    Simply Wall St.2 months ago

    Did BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Insiders Sell Shares?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examplesRead More...